Testing an oral drug for early Alzheimer's disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests an oral tablet (TTYP01) for people with early Alzheimer's disease. It aims to see if the drug can slow memory loss. You must have a study partner who can support you throughout the trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 55 and 85 years old.
- You have been diagnosed with mild cognitive impairment (MCI) due to Alzheimer's or mild Alzheimer's dementia.
- Your memory has been slowly getting worse for at least 6 months, confirmed by a family member or friend.
- You have a study partner (family or friend) who can spend at least 8 hours per week with you during the trial.
- You can have a blood test and a brain PET scan to confirm Alzheimer's-related changes.
- You are generally healthy – no recent stroke, uncontrolled heart disease, or active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental medication called RO7568282 to see if it can slow down memory decline in people with early Alzheimer's disease. If you have early memory problems and a confirmed Alzheimer's-related brain change, you may be able to join.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease (mild cognitive impairment or mild dementia). The goal is to see if it is safe and slows down memory decline.
This trial tests a treatment targeting tau protein buildup in the brain for people with early Alzheimer's. You may join if you have memory or thinking changes but are still living independently, and brain scans show both amyloid and tau clumps.
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
Hear when a new AD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.